Pre-made Setrusumab benchmark antibody ( Whole mAb, anti-SOST therapeutic antibody, Anti-CDD/DAND6/VBCH Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Setrusumab biosimilar, Whole mAb, Anti-SOST Antibody: Anti-CDD/DAND6/VBCH therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Setrusumab is a fully human anti-sclerostin IgG2 monoclonal antibody, being developed by Mereo Biopharma, for the treatment of osteogenesis imperfecta.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-517-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Setrusumab biosimilar, Whole mAb, Anti-SOST Antibody: Anti-CDD/DAND6/VBCH therapeutic antibody
INN Name	Setrusumab
Target	SOST
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2018
Companies	MorphoSys;Novartis;Mereo BioPharma
Conditions Approved	na
Conditions Active	Osteogenesis imperfecta
Conditions Discontinued	Hypophosphatasia;Postmenopausal osteoporosis
Development Tech	MorphoSys HuCAL Phage Display